05 July 2018
U.S. drug contract manufacturer Catalent said it will buy Juniper Pharmaceuticals for $11.50 per share in cash. The offer price represents a premium of about 32 per cent to Juniper Pharmaceuticals’ closing price of $8.70 and values the company at about $127.7 million.
Catalent has a market value of about $5.58 billion.
Juniper Pharmaceuticals shares are up more than 22 per cent since January, when the company said it was exploring strategic alternatives. The deal includes Juniper Pharmaceuticals’ U.K. business, Juniper Pharma Services, and is expected to close in the first quarter of 2019, Catalent said in a statement.
Catalent said it would continue to support Juniper’s Crinone franchise, a progesterone gel which is its single largest revenue source and marketed by Merck outside of the United States. Juniper Pharmaceuticals separately said its board had unanimously approved the deal which represents a total equity value of about $139.6 million on a fully-diluted basis.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
18 January 2021
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
08 January 2021
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
07 January 2021
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.